Correct hematopoietic differentiation requires the tightly regulated execution of lineage-specific and stage-restricted gene expression programs. This process is disturbed in hematological malignancies that typically show incomplete differentiation but often also display a mixed lineage phenotype. Co-expression of lymphoid and myeloid molecules is a well-known feature of acute myeloblastic leukemia (AML) with t(8;21). These cells consistently express the B-cell-specific transcription factor PAX5, and the B-cell-specific cell surface protein CD19. However, the functional consequences of PAX5 expression are unknown. To address this question, we studied the chromatin features of CD19, which is a direct target of PAX5 in cells with and without the t(8;21) chromosomal translocation. We show that CD19 chromatin exists in a poised configuration in myeloid progenitors and that this poised chromatin structure facilitates PAX5-dependent CD19 activation. Our results also show a positive correlation between PAX5 and CD19 expression in t(8;21)-positive AML cells and demonstrate that PAX5 binds to the promoter and enhancer of CD19 gene and remodels chromatin structure at the promoter. This study shows that expression of PAX5 in leukemic cells has functional consequences and points to an important role of a progenitor-specific chromatin configuration in myeloid leukemia.
Introduction
Acute myeloblastic leukemia (AML) is a disease of the bone marrow in which myeloid cell differentiation is arrested in an early stage of development. In many cases, the pathology of AML involves chromosomal aberrations that alter the structure and function of transcription factors controlling genes that regulate cell survival, proliferation and differentiation. RUNX1 (also known as AML1) is a transcription factor that is absolutely required for the formation of definitive hematopoiesis (Okuda et al., 1996; Wang et al., 1996) and is the most commonly mutated gene found at sites of human AML-associated translocations (Speck and Gilliland, 2002) . At least 10 somatically acquired chromosomal translocations involving RUNX1 have been described in AML (Mikhail et al., 2002) . Among these, the translocation between chromosome 8q22 and chromosome 21q22, t(8;21) , is the most common and is associated with approximately 40% of AML-M2 (French-American-British classification) and 8-20% of all AML cases (Peterson et al., 2007a) . The translocation results in the production of a fusion protein that consists of 177 amino acids of RUNX1 containing the Runt domain fused to 575 amino acids of RUNX1T1 (also known as ETO or MTG8). The Runt domain is involved in DNA binding and heterodimerization with CBFb (Kagoshima et al., 1993) whereas RUNX1T1 can interact with several transcriptional co-repressors (Amann et al., 2001) . As a result, the RUNX1-RUNX1T1 fusion protein can recruit transcriptional co-repressor complexes to RUNX1 binding sites and thus represses RUNX1 target genes (Linggi et al., 2002; Follows et al., 2003) . However, ectopic expression of RUNX1-RUNX1T1 in human CD34 þ hematopoietic precursor cells induces both the upregulation and downregulation of a number of genes (Mulloy et al., 2005; Tonks et al., 2007) , indicating that the expression of this oncoprotein disturbs the entire myeloid gene regulatory network. This widespread dysregulation does not only affect myeloid-specific genes. Malignant hematopoietic cells often express lineage-inappropriate genes resulting in a mixed myeloid/lymphoid phenotype (Drexler et al., 1991 (Drexler et al., , 1993 . To date, little is known about the molecular mechanism underlying lineage-inappropriate gene expression in these malignant cells.
In AML with t(8;21) the B-cell-specific cell-surface protein CD19 is frequently co-expressed with myeloid antigens and this is one of the diagnostic hallmarks of this type of leukemia (Kita et al., 1992; Reading et al., 1993) . In normal hematopoiesis, CD19 is expressed exclusively in B lymphocytes and its expression is absolutely dependent on the transcription factor PAX5 (Nutt et al., 1998) . PAX5 is a member of the paired domain family of transcription factors and has an essential role in B-cell specification, commitment and maintenance (Cobaleda et al., 2007) . PAX5 confers Bcell identity by activating B-cell-specific genes and repressing lineage-inappropriate gene expression (Nutt et al., 1999) . Recent studies have shown that expression of PAX5 is also associated with t(8;21) AML (Tiacci et al., 2004; Gibson et al., 2006; Valbuena et al., 2006) .
Our recent study of the developmental regulation of the mouse Cd19 gene shows that epigenetic priming precedes the transactivation of Cd19 by PAX5 during B-cell differentiation (Walter et al., 2008) . In multipotent progenitors, where PAX5 is not yet expressed, the chromatin of the upstream enhancer of Cd19 is already remodeled whereas the promoter is in a poised chromatin configuration. After the onset of PAX5 expression in pro-B cells, Cd19 is transcriptionally activated and mRNA is expressed. The Cd19 locus is epigenetically silenced progressively during non-B-cell differentiation.
Taken together, the co-expression of CD19 and PAX5 suggests the possibility that (1) PAX5 is responsible for the expression of B-cell genes in t(8;21)-positive AML and that (2) gene activation by PAX5 in malignant myeloid precursor cells is facilitated by an accessible chromatin structure of PAX5 target genes.
In the study presented here we tested these hypotheses. We first examined the epigenetic state of CD19 in non-t(8;21) early myeloid cells and show that like its murine counterpart, the human gene exists in a poised chromatin conformation in myeloid precursor cells and AML blast cells without t(8;21). We also show that the ectopic expression of PAX5 activates the expression of endogenous CD19 only in these cells but not in epithelial cells where the chromatin is not accessible. These results were validated in AML blast cells with t(8;21), in which CD19 and PAX5 were co-expressed and PAX5 was bound directly to the CD19 promoter. These results indicate that an accessible chromatin structure of CD19 is a prerequisite for PAX5-dependent CD19 activation. Moreover, we show for the first time that aberrant expression of PAX5 in leukemic cells can have functional consequences and lead to the aberrant activation of B-cell-specific genes.
Results

PAX5
and CD19 are expressed in blast cells from t(8;21)-positive AML Cell-surface expression of the B-cell signal transduction molecule CD19 is one of the prominent characteristics of t(8;21)-positive AML and recent studies showed that the majority of AML cells with this translocation also express PAX5 (Tiacci et al., 2004; Gibson et al., 2006; Valbuena et al., 2006) . We confirmed these observations in our samples by measuring mRNA expression of CD19 and PAX5 in the CD34 þ blast cells purified from patients with or without t(8;21) ( Figure 1 ). The majority of t(8;21)-positive blast cells also expressed CD19 on the surface (Supplementary Figure S1) . Little or no CD19 or PAX5 expression was found in non-t(8;21) AMLs. By analyzing the expression of CD20 as another B-cellspecific marker, we confirmed that the expression of CD19 and PAX5 in t(8;21)-positive AML was not due to a contamination from B cells (Supplementary Figure  S2a) . Two other transcription factors, which were shown to interact with the mouse Cd19 gene, EBF1 and TCF3, were also expressed in these cells (Supplementary Figures S2b and S2c) . TCF3, but not EBF1, was expressed in non-t(8;21) AML.
CD19 cis-regulatory elements are in a poised chromatin configuration in myeloid precursor cells In a recent study we identified a B-cell-specific enhancer within the mouse Cd19 locus (Walter et al., 2008) . Total RNA from the CD34 þ blast cell fraction isolated from AML patients with (P11, P15, P18 and P25) or without (P3, P12, P14, P16 and P24) t(8;21) was used for gene expression analyses. mRNA expression of TBP (control), CD19 (upper panel) and PAX5 (lower panel) was measured after reverse transcription using quantitative real-time PCR. Relative expression levels were calculated as described in the Materials and methods section. CD19 þ and CD34 þ cells isolated from bone marrow mononuclear cells were used as a positive and a negative control, respectively (white bars).
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The human counterpart of this element is situated approximately 1 kb upstream of the transcription start site ( Figure 2a ) and this region also has enhancer activity in human cells (Moreau et al., 2004) . DNase I hypersensitive site (DHS) mapping showed that the enhancer as well as the promoter was hypersensitive in B cells but not in CD19 nonexpressing HeLa epithelial cells (Figure 2b , right and left panels). KG-1 cells represent an early myeloid (myeloblast) cell type that does not express CD19 (Supplementary Figure S3d) and accordingly, the promoter was not DNase I hypersensitive ( Figure 2b , middle panel). However, the enhancer formed a DHS in KG-1 cells (Figure 2b , middle panel), indicating that activation of the enhancer preceded the activation of the promoter. Importantly, this result indicated that the CD19 gene was in a partially active chromatin configuration in human myeloid precursor cells.
To gain further insights into the chromatin fine structure of the CD19 promoter and enhancer, we performed high-resolution in vivo DNase I footprinting using ligation-mediated PCR (LM-PCR). This analysis confirmed that chromatin at the promoter was highly accessible only in RAMOS B cells (Figure 3a) whereas the enhancer was accessible in both RAMOS B cells and KG-1 myeloblasts (Figure 3b ). Interestingly, in KG-1 cells the accessibility at the enhancer was significantly higher than in HeLa but lower than in RAMOS, and the DNase I digestion pattern was different, indicating that the two cell types adopt a differential chromatin architecture. In addition, this experiment confirmed the binding of PAX5 at the promoter in B cells (RAMOS) as indicated by a protection from DNase I digestion at the PAX5 binding site and an increased digestion at neighboring residues (white and black bars in Figure 3a ). We confirmed that we had equivalent levels of DNase I digestion in different samples by assaying the accessibility of the ubiquitously expressed TBP promoter ( Figure 3c ).
Next we asked the question whether the abovedescribed remodeled chromatin pattern was present in other myeloid precursor cell lines as well as in nont(8;21) AML blast cells from patients. To this end, we performed a DNase I accessibility assay using cell lines representing different hematopoietic lineages and blast cells freshly isolated from either the peripheral blood or the bone marrow of patients with non-t(8;21) AML. As shown in Supplementary Figure S4 , both the enhancer and the promoter were highly DNase I accessible in B-cell lines, but not in T-cell lines. In contrast, the enhancer ( Figure 4a ; Supplementary Figure S4a ) but not the promoter (Figure 4b ; Supplementary Figure S4b ) was DNase I accessible in all myeloid precursor cell lines and all tested primary AML blast cells. Notably, the direct comparison showed that the DNase I digestion pattern in primary AML cells was essentially identical to that seen in KG-1 cells. This suggests that the CD19 chromatin fine structure in KG-1 cells is representative of that of AML blast cells whose differentiation is halted at the early stage of myelopoiesis.
We have previously shown in mouse progenitor cells that both the Cd19 enhancer and the Cd19 promoter showed a partially active histone modification pattern, indicating poised chromatin (Walter et al., 2008) , facilitating immediate activation following the binding of PAX5. To test whether this was also true for the human gene, we investigated the histone modification pattern and RNA-polymerase II (RNA Pol II) occupancy at the promoter and the enhancer using chromatin immunoprecipitation (ChIP) assays. Consistent with the DNase I accessibility assays, histones at the enhancer carried active histone marks such as acetyl H3 lysine 9 (H3K9ac) or trimethyl H3 lysine 4 (H3K4me3) (Figures 5b and c) in both RAMOS and KG-1 cells. Furthermore, similar to what we observed at the mouse Cd19 enhancer in progenitor cells (Walter et al., 2008) , the enhancer was bound by RNA Pol II (Figure 5a ). At the promoter, high levels of H3K9ac and H3K4me3 were observed only in RAMOS cells, indicative of an actively transcribing gene. In KG-1 cells, histones at the promoter carried increased levels of monomethyl H3 lysine 9 (H3K9me1) and monomethyl H3 lysine 4 (H3K4me1) (Figures 5d and e) and low level of trimethyl H3 lysine 27 (H3K27me3) (Figure 5d ) whereas HeLa cells showed high levels of the inactive histone mark H3K27me3 throughout the CD19 locus (Figure 5f ). The methylation at H3K4 prevents gene showing hypersensitive sites at À1 kb and the promoter. Genomic DNA from DNase-I-treated cells was digested with HindIII and KpnI and subjected to Southern blot analysis using the probe indicated in (a). Cells used were RAMOS (mature B cells), KG-1 (myeloblasts) and HeLa (epithelial cells). The gel image was generated from grouping different parts of the same gel.
Lineage promiscuity in t(8;21) AML K Walter et al silencing (Ooi et al., 2007) and therefore keeps the locus poised for transcription (Orford et al., 2008) , whereas H3K27me3 is a hallmark of transcriptional repression mediated by polycomb group complexes (Kohler and Villar, 2008) . These data suggest that the CD19 promoter is poised for transcription in KG-1 and epigenetically silenced in HeLa cells, whereby there is no CD19 transcription in either cell line (Supplementary Figure S3c) . Taken together, our data show that similar to what we observed at the mouse Cd19 gene, the human gene also shows an open chromatin configuration at the enhancer and an inaccessible, but poised chromatin state at the promoter in myeloid precursor cells.
PAX5 binds to the CD19 promoter and enhancer in B cells
The specific binding of PAX5 to the human CD19 promoter was shown in a previous study (Kozmik et al., 1992) . In a subsequent study we showed that PAX5 binds to both, the promoter and enhancer, of the mouse Cd19 gene loci (Walter et al., 2008) . This was also true for the human locus. PAX5 binding resulted in the formation of a dimethyl sulfate (DMS) hyperreactive guanine residue at À67 bp within the high-affinity PAX5 binding site at the promoter (Supplementary Figure  S3a) and at À1105, À1106 and À1081 bp at the enhancer (Supplementary Figure S3b) only in B cells. The ChIP assays verified that the PAX5 antibody specifically precipitated CD19 promoter and enhancer chromatin from RAMOS B cells and Nalm6 pre-B cells, but not from KG-1 myeloid cells or HeLa epithelial cells (Supplementary Figure S3c) . These data confirmed that PAX5 binds to the promoter and the enhancer of the human CD19 locus and that this binding can be detected in vivo using small numbers of cells.
Ectopic expression of PAX5 activates the expression of endogenous CD19 in myeloid cells but not in nonhematopoietic cells
We next tested the hypothesis that a poised chromatin structure as described above was a prerequisite for Lineage promiscuity in t(8;21) AML K Walter et al PAX5-dependent CD19 activation. To this end, we transfected a PAX5 expression vector into both KG-1 and HeLa cells and measured the expression of the endogenous CD19 gene. As shown in Figure 6a , ectopically expressed PAX5 activated CD19 gene expression in KG-1 cells but not in HeLa cells. The transfection efficiency was around 50-70% in both cell types as measured by co-transfecting a green fluorescent proteinexpressing vector and both expressed the PAX5 protein at similar levels ( Figure 6b ). Most importantly, ectopically expressed PAX5 could bind to its binding sites in the promoter and the enhancer only in KG-1 cells but not in HeLa cells as measured by ChIP assays (Figure 6c ). Enrichment was lower than in Nalm6 cells, which agreed with the low level of CD19 mRNA expression induced in this system (Figure 6a ). EBF1 is a transcription factor that is absolutely required for PAX5 expression (Decker et al., 2009 ) and, at the same time, is positively regulated by PAX5 (Roessler et al., 2007) . Furthermore, CD19 is also an EBF1 target (Walter et al., 2008) . To test whether the activation of CD19 occurred indirectly through the activation of EBF1, we measured EBF1 expression in PAX5 transfected cells (Figure 6d ) but found it was not induced. Taken together, these results suggest that both PAX5 and an at least partially accessible chromatin structure are required for CD19 activation in early myeloid cells.
PAX5 binding sites are occupied in AML blast cells with t(821)
The experiments described above indicated that ectopically expressed PAX5 is capable of directly activating CD19 in myeloid precursor cells. To test whether this was also true for t(8;21)-positive AML cells, we first examined the chromatin features at the CD19 cisregulatory elements. We first tested whether Kasumi-1 and SKNO-1 cells, which are derived from t(8;21)-positive AMLs and both express the RUNX1-RUNX1T1 fusion protein (Berg et al., 2008) , were a suitable model for such experiments. In these cell lines as well as other myeloid cell lines, HL-60 and U937, the enhancer was accessible to DNase I digestion (Supplementary Figure S4a ). Kasumi-1 cells were originally believed to be CD19-negative, whereas SKNO-1 cells were CD19-positive, reflecting the fact that not all the t(8;21)-positive AML express CD19. However, we failed to detect the expression of CD19 mRNA and protein (Supplementary Figure S3d; data not shown), and the CD19 promoter was not DNase I hypersensitive in both SKNO-1 and Kasumi-1 cell lines (Supplementary Figure S4b ), indicating that the CD19 expression originally detected in SKNO-1 cells (Matozaki et al., 1995) may have been silenced during prolonged culture.
We therefore examined DNase I accessibility in purified blast cells from one patient (P18) with t(8;21) AML in comparison with RAMOS, KG-1 and HeLa cell lines (Figure 7a ). The CD19 enhancer showed a significantly increased accessibility to DNase I in t(8;21) AML blast cells with a pattern resembling that seen in non-t(8;21) blast cells as well as KG-1 cells. However, the pattern at the promoter was different (Figure 7b) . In contrast to KG-1 cells (where the gene was not Figure 4 The promoter and the enhancer of CD19 in non-t(8;21) acute myeloblastic leukemia (AML) blast cells adopt a myeloidspecific, accessible chromatin fine structure similar to that of KG-1 cells. In addition to the cells used in Figure 3 , freshly isolated AML blast cells without t(8;21) (P3, P22, P23 and P25) were treated with DNase I and subjected to ligation-mediated PCR (LM-PCR) with the primers for the noncoding stand of the promoter region (a), the enhancer region (b) and TBP promoter region as a digestion control (c). CD34 þ and CD34 À cells were purified from P3 blast cells using MACS (magnet-activated cell sorting) and then subjected to the DNase I treatment. Symbols are as in Figure 3 .
Lineage promiscuity in t(8;21) AML K Walter et al transcribed and the promoter was DNase I resistant), the promoter in the P18 t(8;21)-positive blast cells showed increased DNase I accessibility downstream of the PAX5 binding site between À100 and À95 bp. Similar to what was observed at the enhancer, the overall pattern of DNase I-dependent digestion differed between RAMOS and P18 blast cells, again indicating a differential chromatin structure between B and myeloid cells.
Next we analyzed whether the increased DNase I accessibility at the CD19 promoter was due to the binding of PAX5. For this purpose we performed in vivo DMS footprinting experiments with blast cells purified from AML patients with or without t(8;21.) Purified þ cells). A similar pattern was observed in blast cells from three patients with t(8;21) AML (P11, P15 and P18) but not in cells without t(8;21) (P3, P14 and P16), suggesting that the PAX5 protein expressed in t(8;21) cells was capable of interacting with its binding site. This was also true for the enhancer where we observed the same DMS hyperreactivity at the PAX5 binding site as in B cells together with several other footprints (Figure 7d ). The footprinting pattern was different from that was observed in Nalm6 pre-B cells. No footprint was seen at EBF1 binding site (note the reduced DMS reactivity at À1117 and À1118 bp in B cells). However, PAX5 was not solely responsible for forming an accessible chromatin structure in t(8;21)-AML cells, as the enhancer was DNase I accessible Cross-linked chromatin was precipitated using antibodies specific for RNA Pol II and specific histone modifications as indicated on the top-right corner of each graph. The precipitated DNA was amplified with primers specific for the CD19 promoter, the CD19 enhancer, the downstream control region ( þ 8.5 kb), the TBP promoter and the Involucrin (IVL) promoter. Relative enrichment was calculated by normalizing against input and to the enrichment observed at the TBP promoter (H3K9ac, H3K4me3, H3K27me3) or IVL promoter (RNA Pol II, H3K9me1, H3K4me1). Each bar is the representative of two independent experiments performed in triplicate.
Lineage promiscuity in t(8;21) AML K Walter et al without detectable PAX5 expression and footprints at the E-box protein binding site were observed in AML blast cells with or without t(8;21). Taken together, our data show that chromatin of the CD19 enhancer is highly accessible in all myeloid precursor cell types (including AML cells), but that the CD19 promoter is bound and activated by PAX5 specifically in t(8;21)-positive AML cells.
Discussion
Lineage-inappropriate gene expression in a proportion of both myeloid and lymphoid malignancies, and in particular in t(8;21)-positive AML, has been known for some time, but the molecular mechanism behind this phenomenon is poorly understood. The study presented here sheds light on the molecular details of aberrant CD19 expression in this type of AML. One important result is that CD19 mRNA is not expressed in multipotent progenitors, suggesting that CD19 needs to be actively induced in these cells. In the mouse, the expression of Cd19 is crucially dependent on the binding of PAX5 at the promoter (Walter et al., 2008) . We show here that there is a positive correlation between PAX5 mRNA expression levels, PAX5 binding and CD19 expression in cells from patients with t(8;21)-positive AML (Figures 1 and 7) , indicating that PAX5 is most likely the major regulator of CD19 in these cells.
The second important finding of this study is that PAX5 is unable to activate epigenetically silenced CD19 chromatin and that a poised and accessible chromatin structure is required for activation. We have previously shown that lineage-specific genes such as Csf1r or Cd19 show similar and equally accessible chromatin structures in multipotent and early lineage-specified progenitors (Tagoh et al., 2004; Walter et al., 2008) . This explains their epigenetic plasticity and why they can revise their cell fate by a single gene alteration even after lineage specification (Kondo et al., 2000; Graf, 2002; Bonifer, 2005) . Our study data add to an increasing body of evidence showing that at early stages of hematopoietic differentiation, the chromatin structure of lineagespecific genes is plastic and alteration of the transcription factor network, including the aberrant expression of transcription factors, can activate lineage promiscuous programs. The study presented here confirms that this also holds true for the perturbation of transcription factor networks in human leukemic cells.
Epigenetic silencing of lineage-inappropriate genes takes place progressively and chromatin becomes less and less plastic during hematopoietic differentiation (Tagoh et al., 2004; Attema et al., 2007; Walter et al., 2008) . For that reason, ectopic activation of CD19 and PAX5 most likely occurs at an early stage of hematopoietic differentiation. Several studies indeed suggest that oncogenic transformation by RUNX1/RUNX1T1 occurs at the hematopoietic stem cell or multipotent Lineage promiscuity in t(8;21) AML K Walter et al progenitor stage (Miyamoto et al., 1996 Elagib and Goldfarb, 2007) . This might also explain why CD19 is co-expressed with CD34 and is downregulated when cells differentiate toward granulocytes (Kita et al., 1992;  Supplementary Figure S1 ). Further experiments using purified human hematopoietic stem cells and progenitor cells will clarify the exact developmental stage at which CD19 can be transactivated by PAX5.
Although PAX5 is most likely the major regulator of CD19 expression in primary t(8;21) cells, the mechanisms by which PAX5 itself is upregulated is not known. A number of results indicate that the partial activation of the B-cell program in these cells is not a simple process. Several experimental systems have been generated to study the molecular action of RUNX1/ RUNX1T1. However, RUNX1/RUNX1T1-transduced Figure S1) . Symbols are as in Figure 3 . In vivo dimethyl sulfate (DMS) footprinting assays at the CD19 promoter (c) and the enhancer (d). In vivo and in vitro (G) DMS-treated DNA was digested and amplified by ligation-mediated PCR (LM-PCR) using primers that detect the noncoding strand of the CD19 promoter and enhancer. The black circle indicates DMS-hypermethylated guanine residues, white circles indicate protections from methylation. Primary cells were isolated from normal bone marrow (CD34 þ and CD19 þ ), peripheral blood (CD3 þ ) or AML blast cells (Figure 1 and Supplementary Figure S1 ). In (d), Nalm6 cells were used as B-cell control. Nucleotide positions relative to the translation start site (ATG) are indicated on the left and the previously determined transcription factor binding sites (Walter et al., 2008) are indicated as a vertical bar on the right of the gel image.
Lineage promiscuity in t(8;21) AML K Walter et al human CD34 þ cells showed neither PAX5 upregulation nor CD19 expression (Mulloy et al., 2005; Tonks et al., 2007) . In addition, AML cells from conditional RUNX1/RUNX1T1 transgenic mice do not express CD19 (data not shown). One possible explanation for these findings is that the activation of PAX5 and CD19 expression requires transformation and a second genetic alteration. However, even an AML created by the induction of RUNX1/RUNX1T1 in combination with other mutations in the mouse still failed to express CD19 (Schessl et al., 2005; Nishida et al., 2006; Peterson et al., 2007b) . It is therefore likely that the formation of CD19 expressing t(8;21) cells in the bone marrow of patients requires additional epigenetic alterations occurring during the selection of highly proliferating transformed leukemic clones.
The levels of CD19 expression in PAX5-transfected cell culture cells were significantly lower than in B cells, and this could not be accounted for by low transfection efficiency. This observation is probably due to the incomplete activation of the B-cell program in this system, as the induced cells failed to express EBF1. We also observed that blast cells from P18 (t(8;21)-AML) did not show EBF binding at the enhancer and expressed CD19 mRNA at significantly lower levels. Although we have not measured the expression of EBF1 protein, the mRNA expression was much lower than in B cells in all tested AML blast cells even with t(8;21) (Supplementary Figure S2 ). An additional possibility for aberrant regulation is the involvement of the myeloidspecific transcription factors, C/EBPa and C/EBPb, that can directly repress the CD19 promoter (Xie et al., 2004) . These factors are downregulated in t(8;21)-positive AML or mutated (Pabst et al., 2001; Mulloy et al., 2005) , raising the possibility that besides aberrant activation, also lack of repression may be involved in the activation of CD19 expression.
Neither the B cell nor the myeloid differentiation program is fully executed in t(8;21) AML cells. These cells remain partially blocked in a myeloid state of differentiation (Kita et al., 1992) and despite the expression of transcription factors PAX5, EBF1 and TCF3 (Figure 1b; Supplementary Figures S2b and c) , which are essential for and can promote B-cell differentiation (Seet et al., 2004; Kwon et al., 2008) , they do not progress to differentiate into B cells and lack B-cell-specific markers such as CD20 and CD21. We therefore propose that the co-expression of transcription factors acting on plastic chromatin and promoting antagonizing gene expression programs is one of the causes for the developmental limbo characteristic for t(8;21) AML cells.
Materials and methods
Human primary cells
Access to the bone marrow and peripheral blood cells from patients and healthy donors was approved by the NHS Research Ethics Committee (Leeds Teaching Hospitals NHS Trust).
Blast cells or bone marrow CD34
þ and CD19 þ cells were purified using density gradient centrifugation or directly from human bone marrow mononuclear cells (Lonza Cologne AG, Ko¨ln, Germany) followed by MACS MicroBeads staining and separation on an AutoMacs separator (Miltenyi Biotech, Bergisch, Gladbach, Germany) according to the manufacturer's instruction. Cell purity was determined by flow cytometry using FITC-CD34, PE-Cy5-CD117 and PE-CD19 antibodies (Miltenyi Biotech or BD Biosciences).
Flow cytometry
The immunophenotype of the AML samples was determined at the Haematological Malignancy Diagnostic Service using the following antibodies: APC-CD34, APC-Cy7-CD45, PerCPCy5-CD19, FITC-CD66c and PE-NG2 (BD Biosciences).
Cell culture RAMOS, JURKAT, Nalm6 and HeLa cells were maintained in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM glutamine, 0.05 mM b-mercaptoethanol and penicillin/streptomycin at 37 1C and 5% CO 2 . KG-1 cells were maintained under the same conditions in Iscove's modified Dulbecco's medium containing the same supplements.
Gene expression analyses
Total RNA isolation, cDNA synthesis and quantitative realtime PCR (qRT-PCR) were performed as previously described (Tagoh et al., 2006) . Relative mRNA levels were calculated using a cDNA standard, and the input was normalized according to TBP mRNA expression.
Transient transfection KG-1 and HeLa cells were transiently transfected with pKW2T or pKW2T-BSAP (obtained from M Busslinger) using the Cell Line Nucleofector Kit R (Lonza Cologne AG) according to the manufacturer's instructions and gene expression, and protein expression was analyzed 24 h after transfection.
Nuclear extraction and immunoblot analysis Nuclear proteins were prepared using a mini-extraction procedure (Schreiber et al., 1989) from 2 Â 10 6 transfected cells. Nuclear proteins (30 mg) for each sample were subjected to immunoblot analyses (Tagoh et al., 2006) using antibodies for PAX5 (AB4227; Millipore, Billerica, MA, USA) and TBP (MAb-TBPCHS; Diagenode, Lie`ge, Belgium).
DNase I hypersensitive site mapping and DNase I footprinting DNase I treatment was performed as previously described (Lefevre et al., 2005) . For DHS mapping, 15 mg of DNase Itreated DNA was digested with KpnI and HindIII to completion and subjected to Southern blot analysis. The positions of the restriction sites and the probe are shown in Figure 2 . For footprinting, 500 ng of DNA was subjected to the LM-PCR (Tagoh et al., 2006) .
In vivo dimethyl sulfate footprinting In vivo DMS footprinting was performed exactly as described previously (Tagoh et al., 2006) . Cells were treated with 0.2% DMS followed by DNA extraction and cleavage by piperidine. DNA lesions formed by DMS and piperidine treatment were visualized by LM-PCR.
